Author:
Janjua Naveed Zafar,Kuo Margot,Chong Mei,Yu Amanda,Alvarez Maria,Cook Darrel,Armour Rosemary,Aiken Ciaran,Li Karen,Mussavi Rizi Seyed Ali,Woods Ryan,Godfrey David,Wong Jason,Gilbert Mark,Tyndall Mark W.,Krajden Mel
Publisher
Public Library of Science (PLoS)
Reference36 articles.
1. Estimated prevalence of Hepatitis C virus infection in Canada, 2011;M Trubnikov;CCDR,2014
2. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection;MS Sulkowski;The New England journal of medicine,2014
3. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1;KV Kowdley;The New England journal of medicine,2014
4. AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1: AbbVie; 2014 [cited 2014 09/02/2014]. Available from: http://abbvie.mediaroom.com/2014-01-31-AbbVie-Completes-Largest-Phase-III-Program-of-an-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Hepatitis-C-Genotype-1#researchAndInnovation.
5. Knox R. $1,000 Pill For Hepatitis C Spurs Debate Over Drug Prices. NPR. 2013.